{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'reported more often after BNT162b2 dose 2 than after dose 1. The vaccine produced a greater', 'immune response in adolescents than adults and was highly effective23', 'Hypersensitivity Reactions and mRNA COVID-19 Vaccines', 'In the Pfizer mRNA phase III trial, more participants reporting hypersensitivity-related adverse', 'events in the vaccine group (137 [0.63%]) compared with the placebo group (111 [0.51%]).', 'There were no anaphylactic or severe hypersensitivity reactions reported (FDA EUA).', 'In the Moderna mRNA COVID vaccine phase III trial, more participants reported', 'hypersensitivity-related adverse events in the vaccine group 1.5% of vaccine recipients (258', 'events in 233 participants) compared with the placebo group 1.1% of placebo recipients (185', 'events in 166 participants). There were no anaphylactic or severe hypersensitivity reactions', 'with close temporal relation to the vaccine. There was one anaphylactic reaction occurring 63', 'days after the second dose of the vaccine that did not meet the Brighton Collaboration', 'Anaphylaxis Case Definition (FDA EUA).', 'There have been numerous reports of anaphylactic reactions after the Pfizer and Moderna', 'vaccine after the start of vaccination campaigns (MMWR January 22, 2021, Vol. 70; MMWR', 'January 15, 2021, Vol. 70). The latest update on anaphylaxis reports to VAERS following', 'mRNA COVID Vaccines through January 18, 2021 (January ACIP meeting), showed following', 'results:', 'Table 4. Anaphylaxis reports to VAERS following COVID-19 vaccines.', 'Table 4. BNT162b2 and Moderna Anaphylactic Reactions', 'Characteristic', 'Pfizer-BioNTech', 'Moderna', '(N = 50)', '(N = 21)', 'Median age, years (range)', '38.5 (26-63)', '39 (24-63)', 'Female (%)', '47 (94)', '21 (100)', 'Minutes to symptom onset,', '10', '10', 'median', 'Symptom onset <15 minutes', '37 (74)', '18 (86)', '(%)', 'Symptom onset <30 minutes', '45 (90)', '19 (90)', '(%)', 'Documented h/o of allergies', '40 (80)', '18 (86)', 'Documented h/o of prior', '12 (24)', '5 (24)', 'anaphylaxis', 'Dose number (1st 2nd unk)', '42,3,5', '19, 1, 1', 'The anaphylaxis reporting rate (analytic period Dec 14 - Jan 18) for the Pfizer mRNA vaccine is', '4.7 per million doses and for Moderna mRNA vaccine, 2.5 per million doses24 Both mRNA', 'vaccines include a warning that anaphylaxis may occur after mRNA vaccines and that', 'appropriate medical treatment for management must be immediately available 25,26', 'Since April 2021, increased cases of myocarditis and pericarditis have been reported in the', 'United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna), particularly in', '15']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'adolescents and young adults after the second dose27 In June 2021, the FDA updated the', 'EUAs for both mRNA COVID-19 vaccines to describe the risk for myocarditis and pericarditis', 'after mRNA COVID-19 vaccines25,26', 'The safety of a booster dose (dose 3) of the Pfizer COVID-19 booster vaccine was assessed in', 'about 300 adults aged 18-55 years. The reactogenicity and safety profile observed after the', 'booster dose was generally similar to that observed after Dose 2 of the initial two-dose', 'vaccination series. Lymphadenopathy was more frequent after dose 3 (5.2%), compared with', '0.4% in persons aged > 16 years after dose 1 or 2. Most cases had axillary lymphadenopathy', 'that resolved within 5 days after onset.', '13,28', 'Influenza and Influenza Vaccine', 'Inactivated influenza virus vaccines (IIVs) have been available in the United States for over 50', 'years and influenza vaccination remains the most effective strategy for reducing the burden of', 'disease caused by influenza. In the United States, vaccination of all persons aged 6 months and', 'older is recommended on an annual basis29. In the 2021-22 influenza season all influenza', 'vaccine formulations are quadrivalent (IIV4) and contain hemagglutinin (HA) from four prototypic', 'influenza types/subtypes that commonly circulate including: influenza A (H1N1pdm09),', 'influenza A (H3N2), and 2 different influenza B lineages (B Yamagata and B Victoria) 29 For', 'adults 65 years of age and older, who may not develop as robust an immune response as', 'younger individuals, both high dose and adjuvanted formulations of IIV4 have been developed.', 'High dose and adjuvanted formulations have been shown to be more immunogenic when', 'compared to standard dose formulations in older adults8. High-dose influenza vaccine has also', 'been shown to be more effective than standard dose influenza vaccine in a randomized clinical', 'trial.', 'Side effects after an inactivated influenza vaccine may include soreness, redness and swelling', 'at the injection site, fever, muscle aches, and headache. There also may be a very small', 'increased risk of Guillain- Barr\u00e9 Syndrome (GBS) or anaphylaxis after an inactivated influenza', 'vaccine', '30', '1.2 Summary and Rationale', 'In clinical practice, the FDA approved the Pfizer-BioNTech COVID-19 vaccine and granted an', 'Emergency Use Authorization for Moderna COVID-19 vaccine in December 2020 and Janssen', 'COVID-19 vaccine in February 2021. Hence, vaccines for both COVID-19 and influenza', 'prevention have the potential for being administered at the same time during early 2021 or later', 'in 2021 when 2021-22 seasonal influenza vaccine is available. To date, neither the Pfizer-', 'BioNTech or Moderna mRNA vaccines have been evaluated for either safety or immunogenicity', 'when co-administered with a non-COVID-19 vaccine. The Phase 3 trial of the AstraZeneca', 'chimpanzee adenovirus-vectored COVID-19 vaccine did not prohibit influenza vaccination but', 'simultaneous administration was not systematically evaluated. Initial guidance from the CDC', 'stated that COVID-19 vaccines should be given alone with at least 14 days either before or after', 'receipt of any other vaccines, including an influenza vaccine, because of limited information on', 'the safety and effectiveness of co-administration. Current guidance now states that COVID-19', 'vaccines can be administered on the same day as other vaccines but mentions that it is', 'unknown if simultaneous administration will affect reactogenicity16,29,31', '16']\n\n###\n\n", "completion": "END"}